SAN RAFAEL, Calif., Nov. 19, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA)…
BioMarin
Achondroplasia is the Most Common Cause of Dwarfism First Medicine Approved to Treat Children with Achondroplasia in Europe SAN RAFAEL,…
via Clinical Trials Arena by William Newton. Vosoritide’s uncertain long-term efficacy may limit European coverage of what could be the…
Source – Fierce Pharma. While BioMarin bested expectations with its second-quarter performance, the biotech is zeroed in on its two next-gen medicines.…
European Commission Decision expected Q3 2021Temporary Authorization for Use (ATU) Granted in France to Allow Access and Reimbursement of Vosoritide…
via Healio/Endocrine Today Children with a common form of skeletal dysplasia saw persistent and sustained improvements in annualized growth velocity…
The Chandler Project 🦋
The Chandler Project provides those affected with achondroplasia, and other forms of dwarfism and skeletal dysplasia, with the latest in pharmaceutical research and surgical advancements. The Chandler Project believes in advocacy, awareness, support, and hope for all.